Sun Pharma up 1.7%; Ranbaxy Pharmaceuticals settles a patent litigation with Actavis

Ranbaxy Pharmaceuticals Inc., a unit of Sun Pharmaceutical Industries, has settled a patent litigation with Actavis over the generic version of Absorica, a drug used to treat acne.

Sun Pharmaceuticals Industries Ltd is currently trading at Rs. 913, up by 1.7% from its previous closing of Rs. 898.2 on the BSE.

Ranbaxy Pharmaceuticals Inc., a unit of Sun Pharmaceutical Industries, has settled a patent litigation with Actavis over the generic version of Absorica, a drug used to treat acne.

The scrip opened at Rs. 909.9 and has touched a high and low of Rs. 915.9 and Rs. 902.25 respectively. So far 1412714(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 216151.48 crore.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1200.7 on 07-Apr-2015 and a 52 week low of Rs. 792 on 17-Oct-2014. Last one week high and low of the scrip stood at Rs. 902.5 and Rs. 840.9 respectively.

The promoters holding in the company stood at 54.71 % while Institutions and Non-Institutions held 31.51 % and 13.78 % respectively.

The stock is currently trading below its 200 DMA.